Celgene (CELG) Partner Acceleron Initiates ACE-536 Phase 2

March 7, 2013 8:16 AM EST Send to a Friend
Acceleron Pharma, Inc., announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. Patients and healthcare providers currently have limited options for the treatment of beta-thalassemia. This is the second ongoing Phase 2 trial for ACE-536, which is being developed by Acceleron as part of a global collaboration with Celgene Corporation (Nasdaq: CELG).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment